ANVS
Annovis Bio Inc.
Company Overview
| Mkt Cap | $45.21M | Price | $3.78 |
| Volume | 712.52K | Change | -8.47% |
| P/E Ratio | -1.8 | Open | $4.15 |
| Revenue | -- | Prev Close | $4.13 |
| Net Income | $-24.6M | 52W Range | $1.11 - $5.60 |
| Div Yield | N/A | Target | $11.67 |
| Overall | 49 | Value | 60 |
| Quality | 23 | Technical | 66 |
No chart data available
About Annovis Bio Inc.
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ANVS | $3.78 | -8.5% | 712.52K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |